RECRUITINGINTERVENTIONAL
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
About This Trial
This research study is evaluating a new method for determining stage and prognosis of individuals with malignant pleural mesothelioma.
Who May Be Eligible (Plain English)
Who May Qualify:
- All adult patients with a diagnosis of malignant pleural mesothelioma undergoing
- diagnostic pleural biopsy
- pleuroscopy
- and/or VATS resections
- Participants must be 18 years of age or older.
Who Should NOT Join This Trial:
-Any patient who is found to be unsuitable for
- surgery,
- treatment
- diagnosis,
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* All adult patients with a diagnosis of malignant pleural mesothelioma undergoing
* diagnostic pleural biopsy
* pleuroscopy
* and/or VATS resections
* Participants must be 18 years of age or older.
Exclusion Criteria:
-Any patient who is found to be unsuitable for
* surgery,
* treatment
* diagnosis,
Treatments Being Tested
OTHER
MPT Test
molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
OTHER
CLDN15/VIM Test
molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
Locations (1)
Brigham and Women's Hospital
Boston, Massachusetts, United States